Jorenby D - Search Results

1

The Promise of Polygenic Risk Prediction in Smoking Cessation: Evidence From Two Treatment Trials.

Bray M, Chang Y, Baker TB, Jorenby D, Carney RM, Fox L, Pham G, Stoneking F, Smock N, Amos CI, Bierut L, Chen LS. Bray M, et al. Among authors: jorenby d. Nicotine Tob Res. 2022 Oct 17;24(10):1573-1580. doi: 10.1093/ntr/ntac043. Nicotine Tob Res. 2022. PMID: 35170738 Free PMC article.

2

Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels.

Stein JH, Bushara M, Bushara K, McBride PE, Jorenby DE, Fiore MC. Stein JH, et al. Clin Cardiol. 2002 Jan;25(1):23-6. doi: 10.1002/clc.4950250107. Clin Cardiol. 2002. PMID: 11808835 Free PMC article. Clinical Trial.

3

Predicting relapse back to smoking: contrasting affective and physical models of dependence.

Kenford SL, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB. Kenford SL, et al. J Consult Clin Psychol. 2002 Feb;70(1):216-27. J Consult Clin Psychol. 2002. PMID: 11860048

4

Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation.

Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Anderson JE, et al. Chest. 2002 Mar;121(3):932-41. doi: 10.1378/chest.121.3.932. Chest. 2002. PMID: 11888979

5

Clinical efficacy of bupropion in the management of smoking cessation.

Jorenby D. Jorenby D. Drugs. 2002;62 Suppl 2:25-35. doi: 10.2165/00003495-200262002-00003. Drugs. 2002. PMID: 12109933 Review.

6

Smoking withdrawal dynamics: I. Abstinence distress in lapsers and abstainers.

Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Piasecki TM, et al. J Abnorm Psychol. 2003 Feb;112(1):3-13. J Abnorm Psychol. 2003. PMID: 12653409 Clinical Trial.

7

Smoking withdrawal dynamics: II. Improved tests of withdrawal-relapse relations.

Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Piasecki TM, et al. J Abnorm Psychol. 2003 Feb;112(1):14-27. J Abnorm Psychol. 2003. PMID: 12653410 Clinical Trial.

8

Targeting smokers at increased risk for relapse: treating women and those with a history of depression.

Smith SS, Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Jamerson B, Fiore MC, Baker TB. Smith SS, et al. Nicotine Tob Res. 2003 Feb;5(1):99-109. doi: 10.1080/1462220021000060437. Nicotine Tob Res. 2003. PMID: 12745511 Clinical Trial.

9

Use of the vital sign stamp as a systematic screening tool to promote smoking cessation.

Piper ME, Fiore MC, Smith SS, Jorenby DE, Wilson JR, Zehner ME, Baker TB. Piper ME, et al. Mayo Clin Proc. 2003 Jun;78(6):716-22. doi: 10.4065/78.6.716. Mayo Clin Proc. 2003. PMID: 12934781 Clinical Trial.

10

Smoking withdrawal dynamics: III. Correlates of withdrawal heterogeneity.

Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB. Piasecki TM, et al. Exp Clin Psychopharmacol. 2003 Nov;11(4):276-85. doi: 10.1037/1064-1297.11.4.276. Exp Clin Psychopharmacol. 2003. PMID: 14599261 Clinical Trial.

Five parameters of postcessation smoking withdrawal variability derived from clinical data (T. M. Piasecki, D. E. Jorenby, S. S. Smith, M. C. Fiore, & T. B. Baker, 2003a, 2003b) were predicted from baseline measures and pharmacotherapy assignment. ...

Five parameters of postcessation smoking withdrawal variability derived from clinical data (T. M. Piasecki, D. E. Jorenby, S. …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

110 results

Search Page